Article Text

other Versions

PDF
Effects of an Ophthalmic Formulation of Meloxicam on COX-2 Expression, PGE2 Release, and Cytokine Expression in a Model of Acute Ocular Inflammation
  1. Raymundo Cruz,
  2. Juan de Dios Quintana-Hau,
  3. Jaime R González,
  4. Rubén Tornero-Montaño,
  5. Leopoldo M Baiza-Durán,
  6. Libia Vega (libia68{at}yahoo.com)
  1. CINVESTAV, Mexico
  2. Laboratorios SOPHIA, Mexico
  3. Laboratorios Sophia, Mexico
  4. Laboratorios SOPHIA, Mexico
  5. Laboratorios SOPHIA, Mexico
  6. CINVESTAV, Mexico

    Abstract

    Aim: To determine the efficacy of meloxicam ophthalmic formulation on COX-2 activity and expression, inflammation-related cytokines expression, and inflammation in an ocular inflammation model.

    Methods: Ocular inflammation was induced in New Zealand rabbits by topical application of croton oil (3%) for 3 h. An ophthalmic solution of 0.03% meloxicam, 0.1% sodium diclofenac, or vehicle (SophisenTM) were administered every 4 h. Conjunctiva, cornea, aqueous and vitreous humor were collected.

    Results: In irritated eyes, 72 h of meloxicam treatment down-regulated COX-2 expression and activity (mRNA by RT-PCR and PGE2 levels by ELISA, respectively) in a time-dependent manner and reduced inflammation. Meanwhile, diclofenac failed to reduce COX-2 mRNA or PGE2 to basal levels after 7 days of treatment. Meloxicam treatment down-regulated IL-6 and IFN-γ expression in the conjunctiva, and IL-1β and TNF-α expression in the cornea. Diclofenac failed to modify these cytokines in both tissues. Meloxicam treatment increased the expression of IL-6 in conjunctiva, and IL-10 in cornea, while diclofenac had no effect on these cytokines.

    Conclusion: Meloxicam treatment was more efficient than diclofenac in down-regulating the expression and activity of COX-2, reducing inflammation, and modifying the inflammatory-related cytokines.

    • AINES
    • COX-2
    • Ocular inflammation
    • PGE2
    • Proinflammatory cytokines

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.